Cancer and Infectious Diseases

Through interdisciplinary collaborations, the cluster aims at discovery and optimization of anticancer and/or antimicrobial lead compounds that combat emerging multidrug resistance. These are validated by in vitro and in vivo models. Our mission is to:

• Design peptides/peptidomimetics and small molecules that combat multidrug-resistant bacterial infections and identify novel targets

• Develop and apply cutting-edge technologies for identification of natural products with
potential as chemotherapeutic leads

• Explore and validate novel anticancer compounds and targets

Paul Robert Hansen / Henrik Franzyk  - Peptide-based Drug Research Group

Kenneth Kongstad / Dan Stærk / Jens Soelberg - Natural Products Research

Jan Stenvang / José Moreira – Molecular Disease Biology

Osman A. Mirza – Drug Transporters Research Group

Fredrik Björkling –  Björkling Group

John Nielsen – Nielsen Group

Karla Frydenvang – Research project

Joseph Rogers – Rogers Group 

Matthias Herth –  Herth Group

Lennart Bunch – Bunch Research Group

1. Novel Cyclic Lipopeptide Antibiotics: Effects of Acyl Chain Length and Position.
   
   
2. Peptide/Peptoid Hybrid Oligomers: The Influence of Hydrophobicity and Relative Side-Chain Length on Antibacterial Activity and Cell Selectivity.
   
   
3. Antimicrobial Activity of α-Peptide/β-Peptoid Lysine-Based Peptidomimetics Against Colistin-Resistant Pseudomonas aeruginosa Isolated From Cystic Fibrosis Patients.
   
   
4. Repurposing Azithromycin and Rifampicin Against Gram-Negative Pathogens by Combination With Peptidomimetics.
   
   
5. Structural analysis of Cytochrome P450 BM3 mutant M11 in complex with dithiothreitol.
   
   
6. ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer.
   
   
7. Four phase 1 trials to evaluate the safety and pharmacokinetic profile of single and repeated dosing of SCO-101 in adult male and female volunteers. 
   
   
8. An Explorative Analysis of ABCG2/TOP-1 mRNA Expression as a Biomarker Test for FOLFIRI Treatment in Stage III Colon Cancer Patients: Results from Retrospective Analyses of the PETACC-3 Trial.
   
   
9. Pharmacodynamic modelling reveals synergistic interaction between docetaxel and SCO-101 in a docetaxel-resistant triple negative breast cancer cell line.
   
   
10. The Pyrazolo[3,4-d]pyrimidine Derivative, SCO-201, Reverses Multidrug Resistance Mediated by ABCG2/BCRP.
    
    
11. Gel-Based Proteomics of Clinical Samples Identifies Potential Serological Biomarkers for Early Detection of Colorectal Cancer.
    
    
12. Metallopeptidase inhibitor 1 (TIMP-1) promotes receptor tyrosine kinase c-Kit signaling in colorectal cancer.
    
    
13. Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene.